REG - Sareum Holdings PLC - New Patent Allowance

Sareum HoldingsAnnouncement

15/03/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240315:nRSO9473Ga&default-theme=true

RNS Number : 9473G  Sareum Holdings PLC  15 March 2024

Sareum Holdings PLC

("Sareum" or the "Company")

New Patent Allowance

Cambridge, UK, 15 March 2024 - Sareum Holdings plc (AIM: SAR), a
clinical-stage biotechnology company developing next-generation kinase
inhibitors for autoimmune disease and cancer, today announces that the
European Patent Office has issued a Notice of Allowance for a patent relating
to SDC‐1801, the Company's lead TYK2/JAK1 kinase inhibitor, currently in
clinical development in Australia.

The newly approved European patent application, EP3864009, safeguards
SDC‐1801, its medical applications particularly in the treatment of
autoimmune diseases, and certain methods of synthesis.

This follows approvals in 2023 by the China National Intellectual Property
Administration, and the Japan Patent Office for the same protections.

Patent applications in the US (US2021387981) and other territories are still
under review.

The Company expects that the patent will be granted in the near future,
subject to certain formalities being completed.

Dr John Reader, Sareum's Chief Scientific Officer, commented: "This new patent
allows us to enhance our intellectual property portfolio in a crucial market.
Our Phase 1a trial for SDC-1801 in Australia is progressing smoothly, with the
Single Ascending Dose (SAD) and Food Effect study revealing no significant
adverse events. This progress highlights the potential of SDC-1801 to achieve
therapeutic drug levels in the bloodstream through once-daily oral dosing."

- Ends -

For further information, please contact:

 Sareum Holdings plc

 Tim Mitchell, CEO                                01223 497700

 Lauren Williams, Head of Investor Relations      ir@sareum.co.uk

 Strand Hanson Limited (Nominated Adviser)

 James Dance / James Bellman                      020 7409 3494

 Peel Hunt LLP (Joint Corporate Broker)

 James Steel / Patrick Birkholm                   020 7418 8900

 Hybridan LLP (Joint Corporate Broker)

 Claire Noyce                                     020 3764 2341

 ICR Consilium (Financial PR)

 Jessica Hodgson / Davide Salvi / Kumail Waljee   0203 709 5700

 

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the Market Abuse Regulation
(EU) No. 596/2014 as it forms part of United Kingdom domestic law by virtue of
the European Union (Withdrawal) Act 2018, as amended by virtue of the Market
Abuse (Amendment) (EU Exit) Regulations 2019 ("UK MAR").

 

About Sareum

Sareum Holdings (AIM:SAR) is a clinical-stage biotechnology company developing
next generation kinase inhibitors for autoimmune disease and cancer.

The Company is focused on developing next generation small molecules which
modify the activity of the JAK kinase family and have best-in-class potential.
Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801
is a potential treatment for a range of autoimmune diseases and has entered
Phase 1a/b clinical development with an initial focus on psoriasis.

Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential
application for cancer immunotherapy.

Sareum Holdings plc is based in Cambridge, UK, and is listed on the AIM market
of the London Stock Exchange, trading under the ticker SAR. For further
information, please visit the Company's website at www.sareum.com
(about:blank)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCEAXDLFAPLEFA